X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (819) 819
Publication (45) 45
Book Chapter (41) 41
Book / eBook (14) 14
Web Resource (8) 8
Patent (4) 4
Conference Proceeding (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (426) 426
hematology (376) 376
index medicus (302) 302
female (293) 293
male (291) 291
adult (289) 289
middle aged (279) 279
transplantation (278) 278
aged (188) 188
adolescent (165) 165
immunology (164) 164
treatment outcome (130) 130
hematopoietic stem cells (126) 126
oncology (125) 125
hematology, oncology and palliative medicine (123) 123
hematopoietic stem cell transplantation (96) 96
hematopoietic stem cell transplantation - methods (95) 95
chemotherapy (94) 94
bone-marrow-transplantation (93) 93
survival analysis (92) 92
young adult (91) 91
disease-free survival (90) 90
transplantation, homologous (86) 86
bone marrow (84) 84
therapy (79) 79
survival (78) 78
retrospective studies (77) 77
transplantation, autologous (77) 77
stem-cell transplantation (76) 76
child (73) 73
recurrence (72) 72
cancer (71) 71
analysis (68) 68
prognosis (68) 68
hemic and lymphatic diseases (64) 64
leukemia (61) 61
stem cells (60) 60
child, preschool (59) 59
transplantation conditioning - methods (58) 58
antineoplastic combined chemotherapy protocols - therapeutic use (56) 56
remission induction (56) 56
blood (54) 54
bone marrow transplantation (54) 54
hematopoietic stem cell transplantation - adverse effects (54) 54
risk factors (54) 54
survival rate (51) 51
acute myeloid-leukemia (50) 50
care and treatment (50) 50
research (45) 45
medicin och hälsovetenskap (44) 44
allogeneic transplantation (43) 43
clinical medicine (43) 43
klinisk medicin (43) 43
medical and health sciences (43) 43
combined modality therapy (41) 41
hematologi (41) 41
mortality (40) 40
cyclophosphamide (39) 39
relapse (39) 39
versus-host-disease (39) 39
abridged index medicus (37) 37
hematopoietic stem cell transplantation - mortality (37) 37
high-dose chemotherapy (37) 37
infant (37) 37
outcomes (37) 37
unrelated donors (37) 37
autologous transplantation (36) 36
hematopoietic cell transplantation (36) 36
health aspects (35) 35
follow-up studies (34) 34
leukemia, myeloid, acute - therapy (34) 34
lymphomas (34) 34
age factors (33) 33
bone-marrow (33) 33
aged, 80 and over (32) 32
aml (32) 32
lymphoma (32) 32
acute disease (31) 31
acute myeloid leukemia (30) 30
children (30) 30
transplantation conditioning (30) 30
risk (29) 29
disease (28) 28
multiple myeloma (28) 28
prospective studies (28) 28
antineoplastic agents - therapeutic use (27) 27
non-hodgkins-lymphoma (27) 27
surgical procedures, operative (27) 27
acute myelogenous leukemia (26) 26
cohort studies (26) 26
patient outcomes (26) 26
precursor cell lymphoblastic leukemia-lymphoma - therapy (26) 26
rituximab (26) 26
autografts (25) 25
colony-stimulating factor (25) 25
graft-versus-host disease (25) 25
leukemia, myeloid, acute - mortality (25) 25
stem cell transplantation (25) 25
lymphoma, non-hodgkin - therapy (24) 24
time factors (24) 24
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Leukemia, ISSN 1476-5551, 2014, Volume 29, Issue 4, pp. 886 - 894
Failure to undergo activation-induced cell death due to global dysregulation of apoptosis is the pathogenic hallmark of large granular lymphocyte (LGL)... 
SURVIVAL | APOPTOSIS | ACTIVATION | INHIBITION | LARGE GRANULAR LYMPHOCYTES | ONCOLOGY | PHOSPHORYLATION | NEUTROPENIA | LYMPHOPROLIFERATIVE DISEASE | STAT3 | FAS | HEMATOLOGY | Leukemia, Large Granular Lymphocytic - drug therapy | Anemia - mortality | United States | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Transcriptome | Male | Methotrexate - therapeutic use | Cyclophosphamide - therapeutic use | Leukemia, Large Granular Lymphocytic - mortality | Neutropenia - complications | Anemia - genetics | Anemia - drug therapy | Neutropenia - mortality | Aged, 80 and over | Female | Neutropenia - genetics | STAT3 Transcription Factor - genetics | STAT3 Transcription Factor - metabolism | Leukemia, Large Granular Lymphocytic - complications | International Cooperation | Gene Expression Regulation, Leukemic | Neutropenia - drug therapy | Anemia - complications | Finland | Survival Analysis | Aged | Mutation | Drug Monitoring | Leukemia, Large Granular Lymphocytic - genetics | Usage | Lymphocytic leukemia | Genetic aspects | Research | Drug therapy | Health aspects | Immunosuppressive agents | Therapy | Profiling | Anemia | Leukemia | Stat3 protein | Activation | Inflammation | Gene expression | Survival | Patients | Confidence intervals | Lower bounds | Cyclophosphamide | Cell activation | Lymphocytes | Cell death | Upper bounds | Biomarkers | Methotrexate | Activation analysis | Neutropenia | Apoptosis | STAT3 Transcription Factor | Leukemia, T-Cell Large Granular Lymphocytic
Journal Article
Leukemia, ISSN 1476-5551, 2015, Volume 29, Issue 8, pp. 1754 - 1762
Clinical outcomes after primary graft failure (PGF) remain poor. Here we present a large retrospective analysis (n = 23 272) which investigates means to... 
ENGRAFTMENT | RISK-FACTORS | ONCOLOGY | BONE-MARROW-TRANSPLANTATION | BLOOD STEM-CELL | ACUTE MYELOGENOUS LEUKEMIA | UNRELATED DONORS | CLASS-I | SEVERE APLASTIC-ANEMIA | HEMATOLOGY | VERSUS-HOST-DISEASE | T-CELLS | Hematologic Neoplasms - therapy | Prognosis | Follow-Up Studies | Myeloablative Agonists - adverse effects | Hematologic Neoplasms - mortality | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Child, Preschool | Infant | Male | Transplantation, Homologous | Young Adult | Graft vs Host Disease - mortality | Hematopoietic Stem Cell Transplantation - adverse effects | Adult | Female | Transplantation Conditioning - adverse effects | Primary Graft Dysfunction - etiology | Retrospective Studies | Hematologic Neoplasms - complications | Child | Graft vs Host Disease - etiology | Infant, Newborn | Primary Graft Dysfunction - drug therapy | Graft Survival | Survival Rate | Graft vs Host Disease - drug therapy | Primary Graft Dysfunction - mortality | Adolescent | Aged | Neoplasm Staging | Care and treatment | Transplantation | Blood diseases | Patient outcomes | Stem cells | Transplants & implants | Syngeneic grafts | Leukemia | Bone marrow transplantation | Grafting | Hematopoietic stem cells | Risk factors | Immunosuppressive agents | Prostaglandins | Granulocyte colony-stimulating factor | Cryopreservation | Failure analysis | Peripheral blood | Bone marrow | Colony-stimulating factor | Busulfan | Conditioning | Incompatibility | Risk reduction | Transplants | ABO system | Risk analysis | Myeloproliferative diseases | Hemopoiesis | Rejection | Cyclophosphamide | Immunosuppression | Grafts | Tacrolimus | Histocompatibility antigen HLA | Leukocytes (granulocytic) | leukemia | myelodysplastic syndrome | myeloproliferative disorders | Allogeneic hematopoietic cell transplantation | myeloablative | primary graft failure
Journal Article
Bone marrow transplantation (Basingstoke), ISSN 0268-3369, 04/2016, Volume 51, Issue 4, pp. 573 - 580
Journal Article
Journal Article
Bone marrow transplantation (Basingstoke), ISSN 1476-5365, 2015, Volume 50, Issue 11, pp. 1416 - 1423
Journal Article
Journal Article
Leukemia, ISSN 1476-5551, 2013, Volume 28, Issue 3, pp. 658 - 665
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2013, Volume 31, Issue 33, pp. 4199 - 4206
Journal Article